Filing Flows › Lifecore Biomedical (LFCR) › Q1 FY27 › vs Q3 FY26
Lifecore Biomedical (LFCR) Q1 FY27 vs Q3 FY26 (quarter over quarter)
Lifecore Biomedical's revenue rose $11.0M (+47%) from $23.2M in Q3 FY26 to $34.2M in Q1 FY27. The biggest changes: HA manufacturing +$11.2M (+151%); CDMO −$223K (-1%).
Lifecore Biomedical, Q1 FY27: revenue $34.2M, operating margin 7.5%, net loss $6.2M, operating cash flow −$2.2M. The chart draws each line against Q3 FY26, the increases inside each band.
Every line
| Line | Q1 FY27 | Q3 FY26 | Change | % |
|---|---|---|---|---|
| HA manufacturing | $18.6M | $7.4M | $11.2M | +151% |
| CDMO | $15.6M | $15.8M | −$223K | -1% |
| Revenue | $34.2M | $23.2M | $11.0M | +47% |
| Net loss | $6.2M | $15.0M | −$8.8M | -59% |
| Costs & expenses | $40.3M | $38.2M | $2.1M | +6% |
| Operating costs | $31.6M | $27.9M | $3.7M | +13% |
| Interest & other, net | $8.7M | $10.3M | −$1.6M | -15% |
| Income tax | $23K | $43K | −$20K | -47% |
| Cost of revenue | $22.1M | $18.7M | $3.4M | +18% |
| Research & development | $1.5M | $1.2M | $320K | +26% |
| SG&A | $8.0M | $7.9M | $54K | +0.7% |
| Operating cash sources | $6.8M | −$692K | $7.5M | — |
| Depreciation | $2.5M | $2.3M | $205K | +9% |
| Share-based compensation | $2.1M | $1.7M | $387K | +23% |
| Cash used in operations | $2.2M | −$4.7M | $6.9M | — |
| Net loss absorbed | $6.2M | $15.0M | −$8.8M | -59% |
| Working capital & other | $633K | −$15.7M | $16.3M | — |
Questions
How much did Lifecore Biomedical's revenue grow quarter over quarter in Q1 FY27?
Lifecore Biomedical's revenue rose $11.0M (+47%) from $23.2M in Q3 FY26 to $34.2M in Q1 FY27.
What drove Lifecore Biomedical's revenue change in Q1 FY27?
HA manufacturing +$11.2M (+151%); CDMO −$223K (-1%).